

BitPath Holdings Launches Gen 2 Digital Asset Treasury Strategy with altFINS Using AI Analytics and Active Management

BitPath's Gen 2 DAT is designed to harness upside from projects at the intersection of blockchain and AI including smart contracts and L1 and L2 networks.

PITTSBURGH, PA, UNITED STATES, August 27, 2026 /EINPresswire.com/ -- BitPath Holdings, Inc.

“

The Gen 2 DAT value creation should be material. Our strategic investments are already producing positive results that will materially improve profitability for BitPath's current quarter.”

Vik Grover, CEO

aka [Bio-Path Holdings, Inc.](#) (OTC: BPTH) today announced the launch of its Gen 2 Digital Asset Treasury (Gen 2 DAT) strategy, designed to harness long-term upside from projects at the intersection of blockchain and artificial intelligence technologies - including smart contracts on Layer 1 and Layer 2 networks, decentralized finance (DeFi), DePIN, and Real World Asset (RWA) tokenization. Our Gen 2 DAT is structured to outperform Gen 1 DAT platforms that typically buy and hold a single cryptocurrency without regard to price cycles. While early pioneers demonstrated that digital assets belong on corporate balance sheets, single-asset buy-and-hold strategies frequently expose

enterprises to severe volatility and concentration risk. To mitigate these hurdles, BitPath's Gen 2 DAT utilizes active management - including long and short positions and derivatives - to capture excess returns across both bull and bear market cycles.

Strategic Partnership and Institutional Analytics

To support its Gen 2 DAT, BitPath has partnered with [altFINS](#), j.s.a., a leading provider of proprietary crypto data analytics utilizing artificial intelligence to identify tactical trading opportunities. To spearhead its digital asset pivot, the Company has appointed altFINS' Founder and CEO Richard Fetyko to its Advisory Board. Fetyko brings 25 years of Wall Street experience as an equity research analyst and tech entrepreneur, alongside a decade of direct involvement in the cryptocurrency industry. In this advisory capacity, Fetyko and the altFINS team will manage BitPath's crypto exchange accounts, deliver weekly performance reports, and provide ongoing guidance for tactical and strategic investments. By marrying technical price trends with rigorous fundamental token metrics analysis, the program adapts dynamically to market cycles rather than relying on passive accumulation.

Transaction Terms and Alignment

To align the long-term interests of both companies:

- BitPath is issuing altFINS 2,561,822 restricted common shares, representing 4.9% of its common shares outstanding,
- BitPath has an option to invest up to two million euros in altFINS for up to a 22% ownership stake,
- altFINS will receive a 1.25% management fee on BitPath's crypto portfolio, alongside performance bonuses tied directly to portfolio profits,
- For his Advisory Board service, Richard Fetyko has been issued 100,000 stock options at market prices,
- The Gen 2 DAT is expected to be funded in part by BitPath's [Qualified Tier 1 Reg A](#) financing of up to \$500,000, with plans to raise up to an additional \$20 million in a subsequent capital raise.

Richard Fetyko, Founder and CEO of altFINS, stated:

"The era of passive 'buy and hold' digital asset treasuries is evolving. While early pioneers proved that cryptocurrencies belong on corporate balance sheets, a Gen 1 single-asset approach exposes companies to unnecessary concentration risk and market volatility. Through our partnership with BitPath Holdings, we are setting a new standard for Gen 2 treasury management - empowering corporate balance sheets with institutional-grade analytics, active risk management, and a diversified, data-driven multi-asset strategy."

Vik Grover, CEO of BitPath Holdings, added:

"Crypto markets are at an inflection point, driven by institutional adoption and a favorable regulatory environment in the U.S. and abroad. The scheduled September 15, 2026 Congressional Hearing on the Clarity Act and recently proposed exemptions for crypto capital raises proposed by the SEC put the industry on the front burner for an explosive transformational period that will reboot our financial system using the block chain. Because there is no reason to invest in a simple buy and hold Gen 1 DAT versus buying the crypto outright or through ETFs, Gen 1 DATs are being eclipsed by Gen 2 platforms using AI and active management that marry technical analysis to fundamental research. I have high expectations for our Gen 2 DAT program. When combined with our crypto social network and token platform, currently under development as are other social platforms, the value creation should be material. Our strategic investments are already producing positive results that will materially improve profitability for BitPath's current quarter. "

ABOUT ALTFINS, J.S.A.

altFINS, j.s.a. is a cloud-based cryptocurrency market analysis and trading platform offering coin

screening, crypto charting, chart patterns, technical analysis, fundamental research, and on-chain data on a subscription basis. Platform features include the following:

- Crypto Screener: Scans thousands of coins using over 150 technical indicators.
- AI Chart Patterns: Automatically detects classic trading patterns like triangles and channels.
- Trading Signals: Provides pre-built trade setups with entry, exit, and stop-loss levels.
- Data API: Offers pre-computed analytics for developers and algorithmic traders.
- Indicators for trading strategies

For further information, sign up for an account and go to altFINS' Telegram channels at the following:

<https://t.me/altfinsofficial>

<https://t.me/altfinsofficialchat>

https://t.me/Signal_Feed_altFINS

ABOUT BITPATH HOLDINGS, INC.

BitPath Holdings, Inc. aka Bio-Path Holdings, Inc. is pivoting to cryptocurrency trading and social media investments in the global market. The Company is a pioneer in MRNA based treatments for rare diseases including acute myeloid leukemia ("AML"). Prexigebersen (Liposomal Grb2 antisense), a lead product candidate, is a neutral-charge, liposome-incorporated antisense drug designed to inhibit protein synthesis of Grb2 (growth factor receptor bound protein 2) that has achieved favorable remission outcomes on initial sample populations. The Company has engaged advisors who are actively exploring partnerships, licenses or sale of the Bio-Path biotechnology platform and data and a restart of its late Phase 2 trial targeting AML.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations and assumptions that are subject to risks and uncertainties that could cause actual results to differ materially. Bitpath undertakes no obligation to update forward-looking statements except as required by law.

BitPath Contact

investors@biopathholdings.com
(630) 708-0750

Vik Grover
BitPath Holdings, Inc.
+1 630-708-0750

[email us here](#)

Visit us on social media:

[X](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/937532653>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2026 Newsmatics Inc. All Right Reserved.